Brii Biosciences Limited
腾盛博药生物科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT
SHARE BUY-BACK PROGRAMME

This announcement is made by the board (the "**Board**") of directors (the "**Directors**") of Brii Biosciences Limited (the "**Company**" and together with its subsidiaries, the "**Group**").

The Board wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors of the Company that the Directors have an intention to exercise their powers under the general mandate (the "**Buy-back Mandate**") granted to the Directors pursuant to the resolutions of the Shareholders passed on June 16, 2026 to buy back shares of the Company (the "**Shares**") not exceeding 10% of the total number of issued Shares (excluding treasury shares (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"))) as at June 16, 2026. In respect of Shares bought back by the Company pursuant to the Buy-back Mandate, the Company may cancel such Shares and/or hold them as treasury shares, depending on, including among other things, market conditions and the Company's capital management needs at the relevant time of the buy-backs.

In view of the current trading price of Shares which is at a level which undervalues the Company's performance, assets value and business prospects, subject to market conditions, on June 17, 2026 (Hong Kong Time), the Board resolved to utilize the Buy-back Mandate by actively undertaking an on-market buy-back programme (the "**Share Buy-back Programme**") of the Shares in the open market from time to time. The total amount of funds to be used for the buy-back of Shares under the Share Buy-back Programme is no more than HK$60 million. The period for the Share Buy-back Programme is from the date of this announcement to the date of the next annual general meeting of the Company to be held in 2027.

The Board believes that the Share Buy-back Programme can further demonstrate the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to the Shareholders. The Board believes that the current financial resources of the Company would enable it to implement the buy-back of Shares under the Share Buy-back Programme while maintaining a solid financial position.

The buy-back of Shares under the Share Buy-back Programme will only be conducted under circumstances which the Board considers to be appropriate and in the interest of the Company and the Shareholders as a whole. The Share Buy-back Programme and the buy-back of Shares will be subject to compliance with the memorandum and articles of association of the Company, the Listing Rules (including but not limited to, not to buy back Shares during the restricted period pursuant to Rule 10.06(2)(e) of the Listing Rules) and all other applicable laws and regulations to which the Company is subject. The buy-back of Shares will be funded by the existing cash resources of the Group. Share bought back may be cancelled and/or held as treasury shares, depending on, including among other things, market conditions and the Company's capital management needs at the relevant time of the buy-backs.

Shareholders and potential investors of the Company should note that any exercise of the Buy-back Mandate to buy back Shares under the Share Buy-back Programme by the Company will be subject to market conditions and at the absolute discretion of the Board. There is no assurance of the timing, quantity or price of any buy-back of Shares or whether the Company will make any buy-back of Shares at all. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, June 17, 2026

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive Directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive Directors.